估算肾小球滤过率、白蛋白尿与不良结局:个体参与者数据荟萃分析
该个体参与者数据荟萃分析纳入1980至2021年114个全球队列,评估基于肌酐的估算肾小球滤过率(eGFR)、基于肌酐联合胱抑素C的eGFR及尿白蛋白肌酐比(UACR)与10种不良结局的关联。结果显示,较低eGFR和较高UACR均与肾脏衰竭、心血管疾病及住院等结局风险升高显著相关,包括最轻度慢性肾脏病类别。
要点
- 基于肌酐的eGFR 45-59 mL/min/1.73 m2者住院率显著高于90-104者(校正HR 1.3)。
- 基于肌酐或肌酐联合胱抑素C的较低eGFR均与10种不良结局风险升高显著相关。
- 较高UACR与所有10种不良结局风险升高显著相关,包括最轻度慢性肾脏病类别。
核心结论
- 在该114个队列的回顾性分析中,基于肌酐的较低eGFR、基于肌酐联合胱抑素C的较低eGFR以及较高UACR均与10种不良结局发生率升高相关,包括不良肾脏结局、心血管疾病和住院。
研究设计与样本
- 个体参与者数据荟萃分析,纳入1980至2021年114个全球队列中27 503 140名个体(基于肌酐的eGFR)。
- 基于肌酐联合胱抑素C的eGFR分析纳入20个队列中720 736名个体。
- 白蛋白尿分析纳入114个队列中9 067 753名个体。
- 各队列内部分析后采用随机效应荟萃分析汇总。
主要发现
- 基于肌酐的eGFR人群(平均年龄54岁[SD 17岁],51%为女性,平均随访4.8年[SD 3.3年])平均eGFR为90 mL/min/1.73 m2(SD 22),UACR中位数11 mg/g(IQR 8-16)。
- 基于肌酐联合胱抑素C的eGFR人群(平均年龄59岁[SD 12岁],53%为女性,平均随访10.8年[SD 4.1年])平均eGFR为88 mL/min/1.73 m2(SD 22),UACR中位数9 mg/g(IQR 6-18)。
- 在UACR低于10 mg/g者中,基于肌酐的eGFR 45-59 mL/min/1.73 m2相较90-104 mL/min/1.73 m2的住院率显著更高(校正HR 1.3 [95%CI 1.2-1.3];每1000人年161 vs 79事件;超额绝对风险22事件/1000人年[95%CI 19-25])。
- 较低eGFR(基于肌酐或基于肌酐联合胱抑素C)和较高UACR均与全部10种不良结局风险升高显著相关,包括最轻度慢性肾脏病类别。
局限性
- 原文在结论中写明该分析为回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Chronic kidney disease (low estimated glomerular filtration rate [eGFR] or albuminuria) affects approximately 14% of adults in the US. OBJECTIVE: To evaluate associations of lower eGFR based on creatinine alone, lower eGFR based on creatinine combined with cystatin C, and more severe albuminuria with adverse kidney outcomes, cardiovascular outcomes, and other health outcomes. DESIGN, SETTING, AND PARTICIPANTS: Individual-participant data meta-analysis of 27 503 140 individuals from 114 global cohorts (eGFR based on creatinine alone) and 720 736 individuals from 20 cohorts (eGFR based on creatinine and cystatin C) and 9 067 753 individuals from 114 cohorts (albuminuria) from 1980 to 2021. EXPOSURES: The Chronic Kidney Disease Epidemiology Collaboration 2021 equations for eGFR based on creatinine alone and eGFR based on creatinine and cystatin C; and albuminuria estimated as urine albumin to creatinine ratio (UACR). MAIN OUTCOMES AND MEASURES: The risk of kidney failure requiring replacement therapy, all-cause mortality, cardiovascular mortality, acute kidney injury, any hospitalization, coronary heart disease, stroke, heart failure, atrial fibrillation, and peripheral artery disease. The analyses were performed within each cohort and summarized with random-effects meta-analyses. RESULTS: Within the population using eGFR based on creatinine alone (mean age, 54 years [SD, 17 years]; 51% were women; mean follow-up time, 4.8 years [SD, 3.3 years]), the mean eGFR was 90 mL/min/1.73 m2 (SD, 22 mL/min/1.73 m2) and the median UACR was 11 mg/g (IQR, 8-16 mg/g). Within the population using eGFR based on creatinine and cystatin C (mean age, 59 years [SD, 12 years]; 53% were women; mean follow-up time, 10.8 years [SD, 4.1 years]), the mean eGFR was 88 mL/min/1.73 m2 (SD, 22 mL/min/1.73 m2) and the median UACR was 9 mg/g (IQR, 6-18 mg/g). Lower eGFR (whether based on creatinine alone or based on creatinine and cystatin C) and higher UACR were each significantly associated with higher risk for each of the 10 adverse outcomes, including those in the mildest categories of chronic kidney disease. For example, among people with a UACR less than 10 mg/g, an eGFR of 45 to 59 mL/min/1.73 m2 based on creatinine alone was associated with significantly higher hospitalization rates compared with an eGFR of 90 to 104 mL/min/1.73 m2 (adjusted hazard ratio, 1.3 [95% CI, 1.2-1.3]; 161 vs 79 events per 1000 person-years; excess absolute risk, 22 events per 1000 person-years [95% CI, 19-25 events per 1000 person-years]). CONCLUSIONS AND RELEVANCE: In this retrospective analysis of 114 cohorts, lower eGFR based on creatinine alone, lower eGFR based on creatinine and cystatin C, and more severe UACR were each associated with increased rates of 10 adverse outcomes, including adverse kidney outcomes, cardiovascular diseases, and hospitalizations.
引用
- Grams ME, Coresh J, Matsushita K, et al. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis. JAMA. 2023. PMID: 37787795. doi:10.1001/jama.2023.17002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。